基于雌激素信号通路的壮骨止痛胶囊治法组方机理探讨
本文选题:壮骨止痛胶囊 切入点:雌激素 出处:《时珍国医国药》2017年04期 论文类型:期刊论文
【摘要】:目的通过检测壮骨止痛胶囊不同治法配伍对去卵巢骨质疏松大鼠骨组织E_2和ER_β的影响,探讨壮骨止痛胶囊的治则组方机理,为临床治疗绝经后骨质疏松症的配伍组方提供指导。方法根据壮骨止痛胶囊补益肝肾、活血止痛治法将处方拆方分为补阳组、补阴组、活血组、阴阳双补组、活血补阳组、活血补阴组。90只8月龄SD雌鼠随机分为假手术组、模型组、壮骨止痛胶囊组、补阳组、补阴组、活血组、阴阳双补组、活血补阳组、活血补阴组,每组10只。假手术组大鼠保留卵巢而只去除卵巢附近部分脂肪组织,其余各组雌鼠双侧去卵巢复制绝经后骨质疏松动物模型,术后1周灌胃给药18周,最后1次给药1 h后腹腔注射水合氯醛麻醉(0.35ml/100g),腹主动脉放血处死,取左股骨检测E_2水平,取右股骨检测骨密度和骨生物力学,快速取右胫骨RT-PCR检测ER_βmRNA的表达,取左胫骨病理切片免疫组化染色检测ER_β蛋白水平。结果活血组对骨密度没有显著影响,但能显著增强骨生物力学,其它配伍组均能显著增加骨密度和改善骨生物力学(P0.05或P0.01),其改善作用从高到低依次为全方组阴阳双补组活血补阳组活血补阴组补阳组补阴组活血组。除活血组外的其它各配伍组均显著提高模型大鼠骨组织E_2水平(P0.05或P0.01)。所有配伍组能显著增强骨组织ER_β的基因和蛋白表达(P0.05或P0.01),作用依次为全方组阴阳双补组活血组活血补阳组活血补阴组补阳组补阴组。结论壮骨止痛胶囊中的活血组药物主要增强骨组织对雌激素的敏感性,补阳组和补阴组药物主要促进机体合成雌激素,提高骨组织的雌激素水平,同时提高骨组织的雌激素敏感性。治疗绝经后骨质疏松治法以补益肝肾为主,辅以活血化瘀,有助于取得更好疗效。
[Abstract]:Objective to investigate the mechanism of Zhuanggu Zhitong capsule (ZZC) by detecting the effect of Zhuanggu Zhitong capsule (Zhuanggu Zhitong capsule) on the bone tissue of ovariectomized rats. Methods according to the prescription of Zhuanggu Zhitong capsule tonifying liver and kidney, activating blood circulation and relieving pain, the prescription was divided into three groups: group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B, group B. Eight-month-old SD female rats were randomly divided into sham-operation group, model group, Zhuanggu Zhitong capsule group, tonifying yang group, invigorating yin group, activating blood circulation group, yin and yang reinforcing group, activating blood circulation and reinforcing yang group, activating blood circulation and nourishing yin group, promoting blood circulation and nourishing yin group. 10 rats in each group: rats in sham-operation group kept their ovaries and only removed some adipose tissue near their ovaries. The other female rats were ovariectomized to make postmenopausal osteoporosis animal model. The rats were given orally for 18 weeks 1 week after operation. One hour after the last administration of chloral hydrate, 0.35 ml / 100 g of chloral hydrate was injected intraperitoneally, and the abdominal aorta was put to death. The left femur was taken to detect the E2 level, the right femur to detect bone mineral density and bone biomechanics, and the right tibia RT-PCR to detect the expression of ER尾 mRNA. The level of ER尾 protein was detected by immunohistochemical staining in pathological sections of left tibia. Results the blood activating group had no significant effect on bone mineral density, but could significantly enhance bone biomechanics. Other compatibility groups can significantly increase bone mineral density and improve bone biomechanics (P0.05 or P0.01). The order of improvement from high to low is the whole prescription group, yin and yang group, activating blood circulation and reinforcing yin group, activating yin group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, activating blood circulation group, and activating blood circulation group. All the compatibility groups could significantly enhance the expression of ER尾 gene and protein in bone tissue of model rats by P0.05 or P0.010.The effect was in the order of activating blood circulation and reinforcing yang in the whole prescription group with both yin and yang invigorating blood circulation group. Conclusion the drugs in Zhuanggu Zhitong capsule mainly enhance the sensitivity of bone tissue to estrogen. The drugs mainly promote the synthesis of estrogen, increase the estrogen level of bone tissue, and increase the sensitivity of estrogen in bone tissue. The treatment of postmenopausal osteoporosis is mainly to invigorate liver and kidney, and to promote blood circulation and remove blood stasis. It is helpful to obtain better curative effect.
【作者单位】: 湖南中医药大学第一附属医院;中南大学湘雅药学院;
【基金】:国家自然科学基金面上项目(No.81273816)
【分类号】:R285.5
【相似文献】
相关期刊论文 前10条
1 姚荣成;陈鹏;何波;杨仁华;王娜;沈志强;;利胆止痛胶囊的药理作用研究[J];中国药房;2013年39期
2 刘延庆,朱健泉,薛永骥,王翊,朱小平,久光正;中药止痛胶囊的抗炎作用研究[J];江苏临床医学杂志;2001年01期
3 寇金矛;冠心止痛胶囊的临床研究[J];河南中医;2003年10期
4 王顺;蔡玉颖;唐惠兰;卢金荣;;川菊止痛胶囊镇痛及活血化瘀作用的实验研究[J];中国中医药科技;2006年02期
5 王宇帆;武鸿翔;;痔疮消炎止痛胶囊的抗炎作用初探[J];云南中医中药杂志;2006年02期
6 董华军;唐丽;王锦伟;;消肿止痛胶囊的制备及临床应用[J];中国误诊学杂志;2008年22期
7 张小超;潘淳;陈鹏;王娜;初贺;沈志强;;利胆止痛胶囊利胆、退黄和保肝作用[J];中药药理与临床;2012年05期
8 陈吉禄;刘洋;曲淑清;何俊莉;丛春娜;;五灵止痛胶囊质量标准研究[J];辽宁中医药大学学报;2007年03期
9 马加庆;陈鹏;沈志强;杨仁华;王娜;李丽;;利胆止痛胶囊对小鼠抗抑菌炎、镇痛和利胆作用研究[J];昆明医学院学报;2011年01期
10 康纪年;周远大;刘岳凤;陶元津;李远宗;朱治本;;复方止痛胶囊实验研究及临床疗效观察[J];中国中西医结合杂志;1995年S1期
相关会议论文 前1条
1 陈芝芳;刘淑静;李岩;;健胃止痛胶囊治疗胃炎和溃疡的实验研究[A];2010年中国药学大会暨第十届中国药师周论文集[C];2010年
相关重要报纸文章 前1条
1 清源;五灵止痛胶囊[N];医药养生保健报;2006年
相关硕士学位论文 前6条
1 冯凯;元胡止痛胶囊的质量控制方法及其金属元素测定研究[D];山东大学;2016年
2 栗会敏;壮骨止痛胶囊B部分无水乙醇部位抗骨质疏松活性成分研究[D];中南大学;2012年
3 雷艳红;痛风止痛胶囊的研究开发[D];长春中医药大学;2008年
4 张琴;复方中药一粒止痛胶囊的质量标准研究[D];重庆医科大学;2005年
5 林清;壮骨止痛胶囊A部分石油醚部位抗骨质疏松活性成分研究[D];中南大学;2012年
6 刘建林;芎芷止痛胶囊治疗偏头痛的实验研究[D];成都中医药大学;2014年
,本文编号:1642453
本文链接:https://www.wllwen.com/yixuelunwen/mazuiyixuelunwen/1642453.html